EcoR1 Capital’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-798,948
Closed -$1.49M 65
2023
Q1
$1.49M Sell
798,948
-2,544,254
-76% -$5.32M 0.05% 50
2022
Q4
$7.69M Buy
3,343,202
+1,421,892
+74% +$4.36M 0.23% 43
2022
Q3
$6.19M Hold
1,921,310
0.18% 44
2022
Q2
$10.6M Buy
1,921,310
+361,600
+23% +$1.12M 0.36% 38
2022
Q1
$3.63M Buy
+1,559,710
New +$5.32M 0.11% 57

Other funds holding GRCL

EcoR1 Capital's GRCL Position: Q2 2023 in Review

EcoR1 Capital sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q2 2023, closing a stake of 798,948 shares — an estimated $1.49M sold.

EcoR1 Capital first reported a position in GRCL in Q1 2022 and held it in 5 quarters. The position peaked at $10.6M in Q2 2022. 36 funds tracked by Wall St. Rank hold GRCL as of Q2 2023.

  • EcoR1 Capital reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q2 2023 after selling out during the quarter.
  • EcoR1 Capital sold 798,948 Gracell Biotechnologies Inc. American Depositary Shares shares in Q2 2023, an estimated $1.49M.
  • EcoR1 Capital first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2022 and held it in 5 quarters.
  • EcoR1 Capital's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $10.6M in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q2 2023.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.